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Abstract
In addition to modulating the function and stability of cellular mRNAs, microRNAs can profoundly affect the life cycles of
viruses bearing sequence complementary targets, a finding recently exploited to ameliorate toxicities of vaccines and
oncolytic viruses. To elucidate the mechanisms underlying microRNA-mediated antiviral activity, we modified the 39
untranslated region (39UTR) of Coxsackievirus A21 to incorporate targets with varying degrees of homology to endogenous
microRNAs. We show that microRNAs can interrupt the picornavirus life-cycle at multiple levels, including catalytic
degradation of the viral RNA genome, suppression of cap-independent mRNA translation, and interference with genome
encapsidation. In addition, we have examined the extent to which endogenous microRNAs can suppress viral replication in
vivo and how viruses can overcome this inhibition by microRNA saturation in mouse cancer models.
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Introduction
MicroRNAs (miRNAs) are a class of small, ,22 nt regulatory
RNAs that modulate a diverse array of cellular activities. Through
recognition of sequence complementary target elements found
most often in the 39UTR of cellular mRNAs, miRNAs post-
transcriptionally regulate numerous cellular processes by way of
mRNA translation inhibition or, less commonly, by catalytic
mRNA degradation. It is thought that upwards of one-third of all
human mRNAs are regulated by the over 700 human miRNAs
that are currently known [1,2]. Many miRNAs can have tissue-
specific localizations and, in addition, some are now known to
have cancer-specific signatures. Cancer-specific miRNAs can be
both oncogenic and oncosuppressive, and growing evidence now
indicates that certain miRNAs are also involved in disease
progression, through the promotion of metastasis [3].
The mechanisms by which a miRNA regulates a given mRNA
are influenced by parameters such as the degree of sequence
homology [4] and target site multiplicity [5] as well as by features
of the mRNA itself, including target site secondary structure [6]
and location [7]. In addition, the cellular machinery used to
translate mRNAs is thought to profoundly affect miRNA
regulation. While capped mRNAs are known to be amenable to
both catalytic miRNA-induced cleavage and miRNA-mediated
translational repression, it has been suggested that uncapped
mRNAs that rely on an IRES (Internal Ribosome Entry Site) for
translation initiation are not susceptible to translational repression
[8][9].
In addition to their roles in the pathogenesis of human disease,
endogenous cellular miRNAs can also play a role in viral infec-
tion, acting to suppress [10][11][12][13] or enhance [14] viral
replication. Recently, miRNAs have been exploited to influence
the tissue tropism and pathogenicity of viruses used as vaccines
[10], anticancer therapeutics [13], and gene transfer vehicles [15].
MiRNAs of both cellular and viral origin are thought to be
involved in regulating the host response to viral infection [16] and
miRNAs have been shown to regulate viral antigen presentation
[17], the antiviral interferon response [18], viral tissue tropism and
antiviral immunity [19].
Engineering miRNA-responsiveness in viruses used as cancer
therapeutics has been shown to be an effective way to generate
tumor selectivity [19]. And although miRNAs clearly play a role in
multiple aspects of both the viral replication cycle and the host
response to viral pathogens, little is known about the mechanisms
by which these regulatory molecules act to directly influence the
level of virus replication. To this end, we engineered the oncolytic
picornavirus Coxsackievirus A21 (CVA21), to encode artificial
miRNA targets complementary to cellular miRNAs. Here, we look
at the ability of these miRNA targets to restrict viral replication in
cells expressing cognate miRNAs and the mechanisms by which
they are able to do so. By utilizing CVA21 derivatives bearing
different miRNA target elements (miRTs), including targets with
varying degrees of homology to endogenous cellular miRNAs and
targets in orientations designed to target either the positive-strand
RNA genome or the negative-strand antigenome, we were able to
identify multiple, distinct steps in the picornaviral life cycle that are
amenable to miRNA-mediated regulation.
CVA21 is a picornavirus known to cause upper respiratory and
inflammatory muscle infections in humans [20][21]. It replicates
quickly and efficiently in both cell culture and in mouse models,
and is a typical positive-strand RNA virus. The genome of CVA21
is a single-stranded, uncapped, positive-strand RNA, which is
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proteases to form the viral capsid and nonstructural proteins. We
have previously reported that CVA21 has potent oncolytic activity
against a variety of human cancers, and can mediate complete
tumor regression in mice bearing human melanoma or myeloma
xenografts [13]. However, this potent and curative oncolytic
activity is accompanied by a high-level viremia and rapid-onset
lethal myositis that hampers the feasibility of employing this virus
as an anticancer therapeutic in the clinic.
Incorporation of miRNA target elements (miRTs) correspond-
ing to two muscle-specific cellular miRNAs (miR-133 and miR-
206) was shown to mediate silencing of CVA21 gene expression in
cells expressing muscle-specific miRNA mimics, in muscle culture
lines and, most importantly, in vivo in mice. Cells expressing
exogenous or endogenous miRNAs complementary to miRTs are
intrinsically immune to infection by the engineered CVA21 and
are protected from the cytolytic effects of this virus. Thus, tumor-
bearing mice infected with a recombinant muscle-restricted virus
(CVA21 miRT) were cured of established tumors whilst being
protected from productive muscle infection and the resultant
myositis. Our ability to engineer the oncolytic picornavirus
CVA21 to contain diverse miRTs provided an opportunity to
look at the mechanisms by which cellular miRNAs can act directly
on a virus to silence gene expression and mediate tumor selectivity.
Results
MicroRNAs can recognize and regulate Coxsackievirus
A21
To investigate at what stage(s) of the viral life cycle cellular
miRNAs are able to perturb viral replication, we utilized our
previous recombinant miRT design whereby four tandem copies
of a given target element corresponding to a cellular miRNA are
incorporated into the 39UTR of the viral genome (Figure 1A). In
order to identify a cellular miRNA that could effectively inhibit
CVA21, we engineered the CVA21 genome to encode tandem
miRTs complementary to four different tissue-specific miRNAs.
Target elements corresponding to muscle-specific (miR-133 and
miR-206), hematopoetic-specific (miR-142-3p) or tumor-suppres-
sor (miR-145) miRNAs were incorporated in the 39UTR of
CVA21 and protection of HeLa cells transfected with sequence-
complementary miRNA mimics (synthetic dsRNAs corresponding
to cellular miRNA duplex intermediates) was analyzed (Figure 1B).
While miRNA-mimics were able to protect cells infected with
viruses containing sequence complementarity from ,60% to levels
that were not significantly different from control, the hematopoe-
tic-specific miR-142-3p target provided the most complete and
most consistent protection, and hence provided the best candidate
to study the different steps of virus replication at which cellular
miRNAs could act to perturb viral replication.
To identify miRNA-mediated antiviral activity acting at distinct
steps in the viral life cycle, we designed a panel of recombinant
viruses expressing variations of the miR-142-3p target. Four
tandem fully complementary sites were designed to provide the
best opportunity for direct catalytic cleavage of the viral RNA
genome and mRNA (CVA21 142T); four copies in reverse
orientation were designed to address the existence of miRNA-
mediated antiviral activity acting on the negative-sense anti-
genome (CVA21 142rT). In addition, two viruses were constructed
to look at the potential for translational silencing of the viral
mRNA: a virus containing 7 base pairs of mismatch between the
target and miR-142-3p (CVA21 mm7T) and a virus that
contained the entire miR-142-3p target site with a 6 base pair
(bp) stuffer sequence inserted between bp 10/11 of the target site
(CVA21 b6T), each with four replicate copies (Figure 1C). The
latter, or ‘bulge’, virus contained extra sequence at the catalytic
cleavage site to provide a strong candidate for miRNA-mediated
translational suppression: four perfect copies of the miRT to
promote miRNA recognition, and a ‘‘stuffer sequence,’’ at the site
at which the RNA induced silencing complex (RISC) ‘slicer’
activity cleaves (to block catalytic degradation of the viral RNA).
These recombinant viruses were rescued in the absence of the
corresponding miRNAs and found to replicate to high titer with
growth kinetics analogous to the wild-type (WT) virus in cells
lacking miR-142-3p (Figure 1D).
Translational silencing of CVA21 mRNA
Cellular microRNAs are known to mediate post-transcriptional
silencing of sequence-complementary mRNAs through transla-
tional repression and/or transcript degradation. However, in the
absence of a 59 cap, and in the presence of the IRESes utilized by
many viruses, it has been hypothesized that miRNAs are unable to
induce translational repression [22]. These studies have been
performed primarily with reporter mRNAs containing one of
several viral IRESes and generally in the presence of short
interfering RNAs (siRNAs), cell free extracts, or miRNA mimics
supplemented in trans [8,23] [24].
Translation of the CVA21 mRNA into the viral polyprotein is
mediated by a type I IRES in a cap-independent manner. We
reasoned that the analysis of recombinant CVA21 variants
targeted by miRNAs might be particularly useful in studying the
translational silencing of cap-independent mRNAs because cells
can be infected at very low multiplicities of infection (MOI), thus
circumventing the potentially confounding issue of miRNA
saturation [25], and enabling the quantitative analysis of virus
expansion whilst simultaneously allowing precise measurement of
cell death at specific times post-infection.
Similar to experiments conducted by other groups [9] [23], we
found that in the presence of miRNA mimics added in trans,
viruses containing multiple imperfectly complementary target sites
were unresponsive to miRNA-mediated repression and cells were
not significantly protected from viral cytopathic effects (Figure 2A).
Author Summary
Virus host range is shaped by cellular determinants such as
transcription factors and receptor expression. In addition,
we have previously shown that tissue-specific microRNAs
can be utilized to direct the specificity of a replication
competent picornavirus, Coxsackievirus A21. In this report,
we demonstrate the mechanism by which microRNAs are
able to directly influence oncolytic viruses, an important
class of anticancer agents. We show that microRNA
expression is an important determinant of permissivity to
oncolytic virus replication, but the actual abundance of
that expression is far more important. In addition, we show
that there are actually multiple different stages in the life
cycle of a replication competent picornavirus that are
amenable to regulation by cellular microRNAs. We proceed
to illustrate that microRNAs can regulate virus tropism in
vivo, but demonstrate that circulating high viral titers in
the blood can overcome this mechanism of conferring
tissue specificity. MicroRNAs are well known to have both
oncogenic or oncosuppressive activities in human cancers.
Here, we show that tissue-specific microRNA expression
can also be used to modulate the efficacy of viral
anticancer therapeutics, and the mechanism by which
they are able to do so.
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increase in protection from cytolysis by these viruses (data not
shown). However, hematopoetic cell lines and primary hemato-
poetic cells expressing high levels of endogenous miR-142-3p were
significantly less susceptible to viruses containing mismatch
(mm7T) or bulge (b6T) targets (Figure 2B; p,0.01 and
p,0.004, respectively). In both cases, viral titers were reduced
by up to 5 orders of magnitude (Figure 2C). Although targeting the
viral antigenome had no significant effect on cell viability, this did
reduce viral titers by up to 100 fold (Figures 2B and 2C).
To determine whether the observed increase in cell viability
was indeed as a result of translational silencing rather than
transcript cleavage, we looked at CVA21 RNA copy numbers. A
panel of hematopoetic cells, as well as H1-HeLa cells (serving as a
c o n t r o lc e l ll i n e )w e r es u p p l e mented with control or miR-142
mimics, and all cells were infected with the panel of recombinant
CVA21 viruses. Total cellular RNA was harvested and viral
RNA was quantified and normalized to cellular GAPDH mRNA
levels. While inserting perfectly complementary miR-142-3p
t a r g e t s( i nC V A 2 11 4 2 T )r e d u c e dC V A 2 1R N Al e v e l sb yu pt oa
million-fold, the mismatched CVA21 mm7T and bulged CVA21
b6T targets induced only a modest decrease in viral RNA
(Figure 2D). Translational silencing would be expected to
indirectly cause a small drop in viral RNA levels through
production of less viral polymerase, presumably accounting for
t h eu pt o4 0f o l dd e c r e a s ei nC V A 2 1R N Ai nt h ep r e s e n c eo f
bulged targets (Figure 2D).
To test whether CVA21 142T RNA was reduced in the
presence of cells bearing sequence-complementary miRNAs due to
direct cleavage of the viral RNA, or rather because translational
silencing had reduced the amount of viral polymerase to amplify
the viral RNA, we performed a trans-complementation experi-
ment. Hematopoetic MEC-1 cells were infected with two different
CVA21s: miRT CVA21 (containing muscle-targets), and CVA21
142T (containing hematopoetic targets). In MEC-1 hematopoetic
cells, CVA21 142T should be miRNA-targeted, while miRT
CVA21 should replicate unencumbered. qRT PCR was then
performed to ascertain the total amount of viral RNA in the cells,
and what portion of it was miRT CVA21 (the difference between
total CVA21 RNA and miRT CVA21 RNA would therefore be
RNA corresponding to CVA 142T in cells doubly infected with
miRT CVA21 and CVA21 142T). Complementation by miRT
CVA21 polymerase should be capable of synthesizing CVA21
142T if any remained that had not been catalytically destroyed,
(however the efficiency of trans-complementation in picornavirus-
es still remains under debate [26][27][28]).
Quantitative PCR analysis revealed that all virus present in
singly infected miRT CVA21 analysis was indeed from miRT
CVA21 (Figure 2E). MEC-1 cells infected with only CVA21 142T
had a larger than 5 log decrease in total CVA21 RNA (and, as
expected did not contain any miRT CVA21). In cells doubly
infected with WT+ miRT virus, less than 50% of progeny
genomes were found to be miRT genomes (the remainder are
therefore WT progeny genomes). However, in cells infected with
Figure 1. Schematics, growth kinetics, and permissivity of recombinant CVA21 in HeLa cells. (A) Schematic diagram of microRNA
insertion in CVA21. (B) Viability of HeLa cells transfected with indicated miRNA-mimics 48 hours post infection with indicated recombinant CVA21. (C)
Schematic overview of miRNA/target homology of recombinant inserts. (D) One -step growth curves of recombinant CVA21s on HeLa cells.
doi:10.1371/journal.ppat.1000820.g001
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found to be miRT genomes (none were therefore 142T genomes).
Hence, 142T genomes are destroyed and not amplified in cells
containing the 142T miRNA, even when the cells are infected with
another virus that provides all viral proteins in trans.
While we observed that the CVA21 142T RNA genome was
profoundly decreased in the presence of perfectly matched miR-
142 mimics, there was significant variability in the degree of
inhibition seen in different hematopoetic cell lines (Figure 2D). To
determine whether this variability correlated with the level of miR-
142-3p expression in these cells, we analyzed the abundance of
endogenous miR-142-3p in our panel of hematopoetic cell lines by
qRT-PCR. The chronic lymphocytic leukemia (CLL) line MEC-1
and the multiple myeloma cell line Kas 6/1 expressed the highest
levels of endogenous miR-142-3p (Figure 2F), and showed the
greatest inhibition of CVA21 142T RNA expression (Figure 2D),
followed by the CLL lines MEC-2, MEC-1, and WAC-3. We
observed an inverse correlation between miR-142-3p expression
levels and the CVA21 142T RNA copy numbers detected,
suggesting that the abundance of this particular miRNA
contributes substantially to the efficiency with which it acts to
silence complementary mRNAs.
Overall these results show that perfectly matched miR-142
targets are recognized and catalytically degraded. In addition,
while clearly not as efficient as mRNA cleavage, translational
repression was seen to occur with cap-independent type I IRES-
containing mRNAs and provided protection from cytopathic
effects mediated by the virus, and the reduced the infectious virus
Figure 2. Translational suppression of CVA21 occurs in the presence of high endogenous miRNAs. (A) Viability 48 hrs. post infection
with MOI=1.0 recombinant CVA21s in the presence of 200 nM control or miR-142 mimic. (B) Viability 48 hrs. post infection with MOI=1.0 in a panel
of hematopoetic or control cell lines or in H1-HeLa cells transfected with 200 nM control or miR-142-3p mimics. (C) Infectious titer in cell supernatant
in (B), titrated on H1-HeLa cells and assayed 72 hrs. post infection. (D) Fold decrease in CVA21 RNA 48 hrs. post infection at MOI=1.0 of
hematopoetic cell lines or in trans supplemented miRNA mimic. Fold decrease normalized to GAPDH expression. (E) Relative CVA21 genome copies in
singly or doubly infected MEC-1 cells as quantified by qPCR. Primers and probes in 2A region of CVA21 or miRT region of CVA21 genome quantified
total or miRT viral genomes, respectively. (F) Relative miR-142-3p abundance in a panel of cell lines. Small RNA was extracted from cells and reverse-
transcription and qPCR analysis of miR-142 3p was performed. Abundance correlated to expression in H1-HeLa cells (per 5 ng small RNA). *p=,.01
vs. H1-HeLa + Control; ND- none detected.
doi:10.1371/journal.ppat.1000820.g002
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was only detected in the presence of high levels of endogenous
miRNAs, however, and at a low multiplicity of viral infection.
Cellular microRNAs perturb the picornaviral life cycle at
multiple steps
Having determined that viral replication was amenable to
miRNA-mediated regulation at two of the earliest steps in viral
infection (genome cleavage after uncoating and initial mRNA
translation), we next sought to look at later steps in the viral life
cycle. While perturbing the virus life cycle at early steps after
infection (attacking genome after uncoating, initial mRNA
expression) would be most likely to slow or inhibit a productive
infection, later steps such as mRNA accumulation, the bulk of
mRNA and genome accumulation, and encapsidation of the viral
genome could be equally amenable to miRNA-mediated regula-
tion as exposed targets are still present on viral RNAs. In order to
examine the ability of microRNAs to act on late steps of viral
replication, we conducted a time-course experiment where
miRNA mimics were added prior to, concomitant with, or at
specific times after infection.
Picornaviruses are known to inhibit host cell translation
beginning at about 1 hour after infection [29], with viral mRNA
accumulation peaking by 5 hours post infection [30], followed by
encapsidation of the positive-strand viral RNA into the provirion
and cytolytic release thereafter [31]. In order to present blocks at
different stages of the picornaviral life cycle, we therefore infected
cells either pre-treated with miRNA mimic, or mimics were added
at 0, 3, or 6 hours post infection (pi).
Analysis of cell viability in the presence of miRNA mimics
added at successive times after infection demonstrated that, while
mimic presence prior to infection provides the greatest protection
from viral cytolysis, miRNAs can negatively impact viral
replication such that cell viability is protected by nearly 50%
even when added 6 hours after infection (Figure 3A). Moreover,
production of viral progeny is greatly diminished in the presence of
miRNAs added at varying time points up to 6 hours post-infection
(Figure 3B). To confirm that this was not an artifact of virus
expansion (ie cells merely being protected by virtue of not being
Figure 3. MicroRNAs inhibit late-stage picornavirus infections. Viability 48 hrs. post infection with (A) MOI=1.0, (C) MOI=3, (E) MOI=10 CVA
142T in the presence of control or miR-142-3p mimic added 4 hours prior to infection, or at 0, 3, or 6 hours post infection. (B) Viral yield from cell
supernatant as measured by TCID50 assay from (A) on H1-HeLa cells. (D) Viral yield from cell supernatant as measured by TCID50 assay from in (C) on
H1-HeLa cells. (F) Viral yield from cell supernatant as measured by TCID50 assay from (E) on H1-HeLa cells. *p=,.01 (as compared to H1-HeLa +
Control).
doi:10.1371/journal.ppat.1000820.g003
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experiment was repeated at an MOI=3 or 10 and similar results
observed (Figure 3C–3F). In addition, we analyzed the quantity of
CVA21 142T by qRT-PCR in the presence of control miRNA
mimics as compared to CVA21 142T infection in the presence of
miR-142-3p mimic at different MOI (Figure 4A) and found that
virus abundance was similar to that observed when analyzed
through infectious titer (Figure 3B, 3D, 3F).
Since the picornavirus life cycle is particularly rapid and the
bulk of viral RNA amplification, protein expression and provirion
production has already taken place by 6 hours after infection, we
wondered whether miRNA mimics might be interfering with
genome encapsidation. We therefore sought to look at the particle:
infectivity ratio of the released progeny viruses in the presence
of miRNA mimics added after viral infection. Infectivity was
determined by titration of cell supernatant on H1-HeLa cells while
capsid protein content was assayed after concentration through
sucrose cushions of the supernatant of infected cells by both
protein assay and Western analysis. Capsid proteins were not
detected in sucrose-purified samples of cellular supernatant to
which sequence-complementary mimics (miR-142-3p) were added
before or simultaneously with CVA21-142T infection (Figure 4B).
However, when miR-142-3p mimic was added 3 or 6 hours after
virus infection, total capsid protein was not significantly dimin-
ished as compared to cells transfected with a control miR (p=0.3,
p=0.14, Figure 4B). Infectious units, however, were decreased by
4 and 3 logs, respectively (Figure 3B). Similarly, when these
sucrose-purified fractions were subjected to Western analysis with
antibodies raised against CVA21, CVA21 protein was roughly
equivalent when CVA 142T infection was performed with in the
presence of control miRNA mimics (Figure 4C). However, miR-
142-3p mimic present 4 hours prior to infection or simultaneously
with CVA 142T infection inhibited detectable expression of
CVA21 capsid in the immunoblot. In contrast, when miR-142-3p
mimic was added at either 3 or 6 hours after expression,
accumulation of viral capsid was detected in Western blots of
the sucrose-purified portion and corresponded with capsid
quantified by protein assay.
Together these results reveal that alternative steps in the
picornaviral life cycle are amenable to miRNA-mediated inhibi-
tion: including (but perhaps not limited to) RNA cleavage after
uncoating, reduced translation of the viral mRNAs, reduced viral
mRNA accumulation, and diminished encapsidation of the viral
genome into the procapsid (Figure 5).
MicroRNAs in vivo: saturation and selective pressure
While the in vitro determination of the mechanisms by which
miRNAs are able to inhibit virus replication can facilitate the
design of better and more elegant ways to exploit cellular miRNAs
for gene transfer and vaccine development for multiple virus
families, in vivo evaluation is necessary to validate this targeting
paradigm for translational purposes, and to demonstrate that it
will indeed occur in model organisms.
Therefore, we next sought to confirm that tumor cells
expressing endogenous miRNAs were capable of targeting the
CVA21 genome and would indeed protect from viral replication
in vivo in the mouse model. To this end, 5610
6 Mel-624
(melanoma) or MEC-1 (chronic lymphocytic leukemia, CLL) cells
were implanted subcutaneously in immunodeficient mice. When
tumors reached an average of 250 mm
3 in size, the animals were
Figure 4. MicroRNAs can affect particle to infectivity ratio of CVA21. (A) Fold change in CVA21 142T RNA as determined by qRT-PCR of viral
RNA from supernatant of infected cells at indicated time pre/post miRNA mimic addition. Fold decrease expressed as ratio of CVA 142T RNA in the
presence of miR-142 mimic/CVA 142T RNA in the presence of control miRNA mimic (at indicated MOI). (B) Protein assay of sucrose-purified virus
collected in the presence of miRNA mimics added at 4 hours prior, or 0, 3, or 6 hours after virus infection at MOI=1. (C) Western blot with anti-CVA21
of sucrose-purified supernatant run on 12.5% SDS-PAGE gel from miRNA mimic timecourse at MOI=1. Lane 1-Control mimic -4 hrs pi + CVA 142T;
Lane 2- 142 mimic -4 hrs pi + CVA 142T; Lane 3- Control mimic 0 hrs pi + CVA 142T; Lane 4- 142 mimic 0 hrs pi +CVA 142T; Lane 5- Control mimic
+3 hrs pi + CVA 142T; Lane 6- 142 mimic +3 hrs pi + CVA 142T; Lane 7- Control mimic +6 hrs pi + CVA 142T; Lane 8- 142 mimic +6 hrs pi +CVA 142T;
Lane 9- Mock infected. BLD- below limit of detection. #p=ns (vs. H1-HeLa + Control mimic). pi: post infection.
doi:10.1371/journal.ppat.1000820.g004
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6 TCID50 of a
recombinant CVA21, after which time tumor growth and survival
were monitored (Figure 6).
As expected, all CVA21 variants (WT, miRT and142T)
replicated in the melanoma-xenografts (which express no
sequence-complementary miRNAs) such that complete (or near
complete) tumor regression took place (Figure 6A). Animals
receiving the WT or 142T viruses rapidly succumbed to myositis,
necessitating euthanasia (Figure 6E). Also as expected, animals
treated with our previously described muscle-restricted virus
(miRT) had complete tumor regressions and were protected from
the development of myositis, while Opti-MEM injected control
tumors grew unencumbered and mice had to be sacrificed when
tumors reached ,2.0 cm
3. In contrast to the melanoma
xenografts, MEC-1 CLL xenografts (which express abundant
miR-142) were susceptible to the WT and muscle-restricted viruses
but were highly resistant to oncolysis by CVA21 142T (Figure 6B).
Since all recombinant viruses behaved as expected in mice
bearing one susceptible or one restricted tumor type, we next
decided to examine their behavior in animals with a different
tumor on each flank after intravenous virus administration. By
using contralateral tumors we were able to create a more
representative in vivo scenario, with multiple CVA21-permissive
tissues having distinct (permissive or restrictive) miRNA expression
profiles. Unexpectedly, the virus bearing tandem repeats of miR-
142 (CVA21 142T) replicated in both the permissive melanoma
xenograft (Figure 6C) and in the ‘‘nonpermissive’’ CLL xenograft
(Figure 6D) in these mice, such that both tumors regressed just as
rapidly as when they were infected with the nontargeted WT or
miRT viruses. Once again, only the muscle restricted virus (miRT
CVA21) prolonged the survivals of tumor-bearing mice, (Figure 6E
p=0.0018, Figure 6F p=0.0004, Figure 6G p=0.0062).
To confirm that CVA 142T was indeed replicating in both the
melanoma and myeloma xenografts, both tumors were explanted
from two separate mice at time of euthanasia. Tissue was
homogenized and overlaid on H1-HeLa cells to look for viral
recovery. In each tumor of both animals, virus was recovered and
found to contain no alteration in the 142T sequence, indicating
that there was indeed productive infection in both tumors.
In order to determine why regression of mir-142-expressing
hematopoetic tumors was observed in animals bearing contralat-
eral melanoma xenografts when treated with the miR-142
restricted virus, but not in animals with a single hematopoetic
tumor, we compared the viral titers in serum from animals treated
with CVA21 142T versus WT CVA21 (Figure 6H). Serum titers
were typically high in mice treated with WT CVA21, irrespective
of whether they were implanted with melanoma, CLL or bilateral
xenografts. In mice treated with CVA-142T, the serum titers were
very high (.10
8) in animals bearing melanoma xenografts, very
low (,10
2) in those with hematopoetic tumor xenografts, and were
again very high in animals with the combination of melanoma and
hematopoetic xenografts on either flank.
Since serum titers were very high in mice with bilateral tumors
(.10
8 TCID50/ml), we investigated the possibility that endoge-
nous miR-142 expressed in MEC-1 xenografts could have been
saturated by this high-level viremia. To investigate this possibility,
we conducted an in vitro assay looking at saturation of endogenous
miR-142 in MEC-1 cells. While cells were completely protected
against cytotoxicity at MOIs of up to 30, increasing virus titer
thereafter resulted in decreased cell viability such that by an
MOI=1,000 we saw near complete cytopathic effects in CVA21
142T infected cells (Figure 6I), thus suggesting that the
endogenous miR-142 may have been effectively saturated, a
phenomenon which has been observed by a number of groups
previously [32] [25]. While our in vitro data suggest that a
sequence-specific saturation of endogenous miRNAs is possible,
other possibilities include a non-specific shutdown of all RNAi
machinery in infected cells, or possibly the destruction of tumor
vasculature that serves as a necessary scaffolding for xenografts.
Together these data show that miRNAs act in vivo to restrict virus
tropism in cells permissive to viral replication. Perhaps not surprisingly,
we found that persistent high-level viremia was able to overcome this
miRNA-mediated restriction, possibly through allowing the saturation
of endogenous miRNAs for which our virus bore tandem cognate
targets. We speculate that in animals bearing bilateral tumors treated
with intravenous CVA21 142T, virus trafficked to the susceptible
melanoma tumor, which created a reservoir of viral amplification. This
then resulted in a high-level viremia, which was able to overwhelm the
miRNA-restricted CLL tumor by saturating the sequence-comple-
mentary endogenous miRNA. We detected no sequence alteration in
the virally encoded miRT insert in animals treated with miRT or
CVA21 142T, and therefore can dismiss the possibility that the viruses
overcame miRNA restriction in this manner. However, we did identify
significant sequence insert changes in viruses bearing the tumor
Figure 5. RISC-mediated inhibition of CVA21 life cycle. Stages in the picornaviral life cycle at which miRNAs could potentially act: 1-genome
attack after uncoating; 2-polyprotein translation; 3-negative strand RNA synthesis; 4- positive strand RNA accumulation; 5-encapsidation.
doi:10.1371/journal.ppat.1000820.g005
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PLoS Pathogens | www.plospathogens.org 7 March 2010 | Volume 6 | Issue 3 | e1000820Figure 6. MicroRNAs regulate virus tropism in vivo, but can be saturated by high-level viremia. (A) SCID mice bearing Mel-624
xenografts were treated with one intratumoral dose of 1610
6 recombinant CVA21 and tumors measured daily. (B) SCID mice bearing MEC-1
xenografts were treated with one intratumoral dose of 1610
6 recombinant CVA21 and tumors measured daily. (C) SCID mice bearing bilateral Mel-
624 and MEC-1 xenografts were treated with one intravenous dose of 1610
6 recombinant CVA21 and Mel-624 tumors measured daily. (D) SCID mice
bearing bilateral Mel-624 and MEC-1 xenografts were treated with one intravenous dose of 1610
6 recombinant CVA21 and MEC-1 tumors measured
daily. (E) Kaplan-Meier survival graphs of mice in (A). (F) Kaplan-Meier survival graphs of mice in (B). (G) Kaplan-Meier survival graphs of mice in (C,D).
(H) Virus titer in mouse serum in mice from (A–D). (I) In vitro saturation of miR-142 as determined by MTT assay in MEC-1 cells infected with rCVA21 at
MOI .1-1000.
doi:10.1371/journal.ppat.1000820.g006
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animals (data not shown). We therefore surmise that miRNA targets
are differentially effective and susceptible to different selective pressures
to mutationally inactivate these targets,and that this may correspond to
the specific tissues from which they are being excluded.
Discussion
Increasing insights into the interactions between miRNAs and
viruses have suggested new therapeutic targets for antiviral drugs
and new techniques for the creation of vaccines, as well as for
regulating the tissue specificity of gene transfer vehicles and
oncolytic viruses. However, the ways in which cellular miRNAs
can act to inhibit viral replication have remained ill-defined. In
this report, we identify alternative steps in the viral life cycle that
are amenable to miRNA-mediated inhibition in the context of a
replication-competent oncolytic virus that acts as a fully curative
therapy in xenograft-bearing mice.
Here, we show that picornaviruses are most susceptible to
miRNA-mediated attack immediately after infection, and that the
viral RNA genome can be recognized and cleaved by fully
sequence complementary miRNAs. However, contrary to the
currently accepted paradigm, we also present evidence to suggest
that miRNAs can translationally suppress uncapped, IRES-
dependent mRNAs bearing imperfectly matched target sequences
at low multiplicity of infection. Several previous studies have used
the tumor-suppressor miRNA let-7a to look at miRNA regulation
in cap dependent vs. IRES dependent mRNAs. However, despite
very high let-7a abundance in a number of cell lines, target
elements corresponding to let-7 do not functionally suppress
sequence complementary targets as efficiently as does miR-142 (or
a number of other well-characterized miRNAs) [5]. In addition,
the interpretation of data generated using cell-free extracts and
synthetic miRNAs supplemented in trans, as employed previously
by several groups, may be made more difficult by miRNA
saturation. We believe the use of a highly efficient miRNA target
(miR-142T), cell lines expressing high levels of endogenous,
sequence-complementary miRNAs, and the ability to infect cells at
low MOI, have enabled us to see the subtle translational
suppression of a viral mRNA in a cap-independent context.
The observation that the picornaviral life cycle can be efficiently
interrupted by miRNAs even at very late stages after infection, by
which time the viral genome copy number has amplified to a very
high level, is truly remarkable. This late interruption appears to
require perfect complementarity between the viral genome and the
miRNA, and probably in large part reflects the rapid catalytic
destruction of viral genomes. An interesting consequence of
adding the miRNA late after infection to interrupt the viral life
cycle is that the cell still releases abundant virus particles, but that
they lack infectivity (Figures 3, 4). The possibility exists that
miRNAs could also block encapsidation of viral RNA genomes by
steric hindrance (RISC bound-RNAs being too large to be
packaged), although our data do not address this possibility.
While our data show that miRNAs can recognize and
antagonize a virus, our observation that endogenous cellular
miRNAs can actually overwhelm this regulation is also of potential
importance. The phenomenon of miRNA saturation, whereby
miRNA targets can act as ‘sponges’ to bind and sequester
endogenous cellular miRNAs, has been reported previously, but
has been generally thought to occur in the context of translational
silencing [25] [32]. Here, we show that miRNA saturation can also
occur when miRNA regulation is occurring primarily by catalytic
degradation of a perfectly complementary RNA target (Figure 6I),
and that it can happen in the context of viral infection in vivo.
We have shown that miRNAs can suppress virus propagation in
vivo and can provide post-entry blocks to virus replication in
otherwise permissive cells. However, we also show that miRNA
defenses can be overcome at very high multiplicities of viral
infection in vivo, allowing unencumbered virus replication.
Therefore, clinicians considering therapeutic intervention utilizing
miRNA targeted-viruses (ie vaccines and cancer therapeutics) must
be particularly wary of the possibility that unencumbered virus
replication in permissive cells, eg a tumor, may eventually lead to
viral infection and pathogenesis in normal cells that express a
restricting miRNA (if that miRNA becomes saturated).
MiRNAsareknownfortheirability toregulatenumerous cellular
functions, often at multiple steps within a single signal cascade. In
this report, we have shown that miRNAs can also act to antagonize
sequence complementary viruses at multiple, alternative steps in the
virus life cycle such that tumor selectivity is generated, but also a
mechanism by which this can be overcome. Although we show that
picornaviruses are particularly susceptible to miRNA interference,
the different replication steps affected by miRNAs are common to
many viruses and it is therefore likely that multiple virus families will
be amenable to miRNA-mediated regulation.
Materials and Methods
Ethics statements
Mayo Clinic Institutional Care and Use Committee reviewed
and approved protocol A7007 with investigators SJR, EJK, and
EMH, entitled ‘‘MicroRNA-mediated targeting of an oncolytic
enterovirus, Coxsackievirus A21’’. All mice were housed in the
BSL-2 facility at Mayo Clinic and experiments were performed in
compliance with outlined and approved institutional guidelines.
Cell culture
H1-HeLa, cells were obtained from American Type Culture
Collection and were maintained in DMEM supplemented with
10% FBS in 5% CO2. MEC-1, MEC-2, WAC-3, and Kas 6/1
cells were obtained from Diane Jelenik, Dept. of Immunology,
Mayo Clinic. MEC-1 and MEC-2 cells were maintained in
IMDM 10% FBS in 5% CO2. WAC-3 and Kas 6/1 cells were
cultured in RPMI with 10% FBS in 5% CO2.
Recombinant CVA21 construction
pGEM-CVA21 clone was kindly provided by Matthias Grome-
ier. miRNA sequences were obtained from the Sanger Institute
miRBase (http://microrna.sanger.ac.uk/sequences/). The follow-
ing sequences were cloned into the 39UTR of pGEM-CVA21 in
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Viral RNA was produced using Ambion Megascript and
Megaclear T7 polymerase kit according to manufacturers
instructions. For rCVA21 rescue 1 ug RNA/well was transfected
into H1-HeLa cells in 12 well plates using the Mirus RNA
transfection reagent and at 24 hours post infection wells were
scraped and cell pellets harvested. Cell pellets were subjected to 3
freeze/thaw cycles in liquid N2, cell debris was cleared by
centrifugation and cleared lysate was added to H1-HeLa cells in a
T-75 flask. Titration of CVA21 was performed on H1-HeLa cells.
Cells were plated in 96 well plates at 50 percent confluence. After
24 hours, serial ten-fold dilutions (22t o210) were made of the
virus; 100 uL of each dilution was added to each of eight duplicate
wells. Following incubation at 37uC for 72 hours, wells were then
assessed for CPE and TCID50 values were determined using the
Spearman and Ka ¨rber equation.
One-step growth curves
H1-HeLa cells were incubated with rCVA21 at a multiplicity of
infection (MOI, determined by TCID50 per cell) of 3.0 for 2 hours
at 37uC. Following this incubation, cells were washed and
resuspended in fresh growth media at predetermined time-points
(2, 4, 6, 18, 12, 24, hours), cells pellets were harvested and frozen
at 280uC. At the completion of all time-points, they were thawed,
and cell pellets were cleared from the samples by centrifugation
providing a cleared cell lysate fraction.
MiRNA mimics
miRNA mimics were purchased from Dharmacon, Inc. Control
miRNA mimic corresponded to a C. elegans miRNA with no
predicted miRTs in mammalian cells according to manufacturer.
miRNA mimics were transfected with Mirus
TM RNA transfection
reagent at a 200 nM concentration. 4 hours post mimic
transfection, cells were infected with recombinant CVA21 at
MOI=1.0, 3, or 10, unless other time noted. After 24 hrs. post
infection, cells were harvested for MTT viability assay and
supernatant was harvested for titration.
Quantitative RT-PCR
Total cellular RNA was harvested using the Qiagen RNeasy
Kit, according to manufacturer instructions. Primers and probes
corresponding to the 2A region or miRT insert region of CVA21
were used to quantitate CVA21 RNA and GAPDH primers and
probes were used to normalize total cellular RNA. For each
sample analyzed, 50 ng of total RNA was subjected to qRT-PCR
in triplicate on Stratagene Mx4000 qPCR system using the
Taqman One Step RT PCR master mix.
MicroRNA analysis
Small RNAs were harvested from all cell lines with the Ambion
miRVana microRNA isolation kit, according to manufacturer
instructions. RNA was resuspended in 50 ul nuclease free water,
and quantified by spectrophotometer. For analysis of miRNA
expression, the Applied Biosystems Taqman microRNA Assay
system was used. For each miRNA analyzed, 5 ng of small RNA
was subjected to qPCR in triplicate on Stratagene Mx4000 qPCR
system.
Viral particle quantification
Ten-centimeter dishes of H1-HeLa cells were transfected with
miRNA mimics and infected with CVA21 142T at MOI=1.0 at
indicated time points. Cell supernatant was collected centrifuged
for 5 mins at 10,000 g to clear cell debris. Infectious titer was
calculated on cell supernatant, and thereafter .5% SDS and 2 mM
EDTA was added to supernatant, and then overlaid on a 5 ml
sucrose cushion. Total virus particles were subjected to ultracen-
trifugation for 4 h at 28,000 rpm using an SW28 swinging bucket
rotor. Supernatants were discarded and centrifuge tubes were
rinsed with PBS and re-spun. After PBS wash, virus pellets were
resuspended in PBS containing 0.2% SDS and 5 mM EDTA.
Virus capsid protein was then quantified using Biorad protein
assay kit and normalized to mock infected and concentrated
samples.
CVA21 antibody generation
Twenty female Balb/C mice were inoculated intraperitoneally
with 1e6 CVA21 three times over a period of six weeks. Two
weeks following the final inoculation, mice were terminally bled,
serum was collected and pooled and frozen at 220uC for use in
immunoblotting.
Western blot analysis
Supernatant from miRNA-mimic timecourse experiments were
sucrose-purified as above and run on a 12.5% SDS page gel and
transferred to a PVDF membrane using the Trans-Blot SD semi-
dry transfer apparatus (BioRad) for 45 minutes at 15 Volts. Blots
were blocked in TBS-10% milk for 1 hour at room temperature.
Primary CVA21 antibody generated as described above was
diluted 1:500 in TBS-5% milk +.05% Tween and blots were
incubated overnight at 4uC. Membranes were washed in TBS
+.1% Tween and incubated in secondary Goat-Anti Mouse IgG
(Dako) at a 1:5000 dilution in TBS-5% milk+.05%Tween at room
temperature for 1 hour. Membranes were washed in TBS +.1%
Tween and bound antibodies were detected using SuperSignal
West Pico Chemluminescent reagent (Pierce).
In vivo experiments
All animal protocols were reviewed and approved by Mayo
Clinic Institutional Care and Use Committee. CB17 ICR-SCID
mice were obtained from Harlan. Mice were irradiated and
implanted with 5e6 Kas 6/1 or Mel 624 cells in the right flank.
When tumors reached an average of .56.5 cm, tumors were
treated with 1e6 CVA21. Tumor volume was measured using a
hand held caliper and blood was collected by retro-orbital bleeds.
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